Japan calls for proper use of diabetes drug Mounjaro

In a notice to medical institutions, sent through prefectural governments, the ministry said such use could lead to unexpected health hazards. It also posted a warning to the public on social media.

"We'll take necessary measures to prevent health problems," health minister Kenichiro Ueno told a press conference.

Mounjaro is approved in Japan as a treatment for type 2 diabetes under the public health insurance system.

However, some medical institutions prescribe the drug for off-label cosmetic and weight-loss purposes under private medical care not covered by the public insurance.

In addition, some people sell the drug via social media without permission.

The ministry said in its notice that off-label prescriptions of Mounjaro require "sufficient caution," as their safety and efficacy have not been proven and they may result in adverse health effects.

As side effects such as low blood sugar and acute pancreatitis may occur even at approved doses, the ministry requested medical institutions to fully explain the risks associated with the drug to patients and prepare systems to deal with patients suffering adverse effects.

The ministry also urged medical institutions to take measures not to cause supply shortages for patients who truly need the medication.